Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.
- DOI
- 10.1007/s00280-020-04173-2
- Published
- 2021 Jan
- Container
- Cancer chemotherapy and pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00280-020-04173-2,
title = {Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.},
author = {Taflin H and Odin E and Carlsson G and Tell R and Gustavsson B and Wettergren Y},
year = {2021},
journal = {Cancer chemotherapy and pharmacology},
doi = {10.1007/s00280-020-04173-2},
url = {https://doi.org/10.1007/s00280-020-04173-2}
}RIS
TY - JOUR TI - Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin. AU - Taflin H AU - Odin E AU - Carlsson G AU - Tell R AU - Gustavsson B AU - Wettergren Y PY - 2021 JO - Cancer chemotherapy and pharmacology DO - 10.1007/s00280-020-04173-2 UR - https://doi.org/10.1007/s00280-020-04173-2 ER -
APA
H, T., E, O., G, C., R, T., B, G., & Y, W. (2021). Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.. Cancer chemotherapy and pharmacology. https://doi.org/10.1007/s00280-020-04173-2
Source records
- pubmed · retrieved 2026-09-26T18:18:32.322Z